Intellectual Property Cases filed in Delaware
Cases 31 - 40 of 209
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
as 1:2020cv00093
Defendant: Teva Pharmaceuticals USA, Inc.
Plaintiff: Vanda Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 1
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
as 1:2019cv02202
Defendant: Teva Pharmaceuticals USA, Inc.
Plaintiff: Vanda Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 1
IBSA Institut Biochimique SA et al v. Teva Pharmaceutical USA, Inc.
as 1:2019cv02115
Plaintiff: Altergon SA, IBSA Pharma Inc. and IBSA Institut Biochimique SA
Defendant: Teva Pharmaceutical USA, Inc.
Cause Of Action: 35 U.S.C. § 271
Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. et al We have downloadable decisions or orders for this case
as 1:2019cv01979
Defendant: Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA Inc., Lupin Inc. and others
Plaintiff: Novartis Pharmaceuticals Corporation
Cause Of Action: 35 U.S.C. § 271
Otsuka Pharmaceutical Co., Ltd. et al v. Teva Pharmaceuticals USA, Inc. et al
as 1:2019cv01955
Defendant: Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.
Plaintiff: Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Cause Of Action: 35 U.S.C. § 271
In re: Palbociclib Patent Litigation
as 1:2019md02912
Not Classified By Court: Aizant Drug Research Solutions Pvt. Ltd., Hetero USA Inc., Teva Pharmaceuticals USA, Inc. and others
In Re: In re: Palbociclib Patent Litigation
Cause Of Action: 35 U.S.C. § 271
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
as 1:2019md02902
Counter Defendant: Merck Sharp & Dohme Corp.
Not Classified By Court: Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and others
Counter Claimant: Macleods Pharmaceuticals Limited
In Re: In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
Defendant: Accord Healthcare, Inc., Teva Pharmaceutical Industries Ltd., Inventia Healthcare Ltd. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Auryxia (Ferric Citrate) Patent Litigation
as 1:2019md02896
Not Classified By Court: Chemo Research S.L., Insud Pharma S.L., Teva Pharmaceuticals USA, Inc. and others
Counter Defendant: Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc. and Chen Hsing Hsu
Counter Claimant: Lupin Atlantis Holdings SA and Lupin Ltd.
In Re: In re: Auryxia (Ferric Citrate) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
LEO Pharma A/S et al v. Teva Pharmaceuticals USA, Inc.
as 1:2019cv01282
Defendant: Teva Pharmaceuticals USA, Inc.
Plaintiff: LEO Pharma A/S, Foamix Pharmaceuticals Ltd. and LEO Pharma Inc.
Cause Of Action: 35 U.S.C. § 271
Keryx Biopharmaceuticals, Inc. et al v. Watson Laboratories, Inc. et al
as 1:2019cv00885
Plaintiff: Keryx Biopharmaceuticals, Inc. and Panion & BF Biotech, Inc.
Defendant: Watson Laboratories, Inc., Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals USA, Inc.
Cause Of Action: 35 U.S.C. § 271

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?